NCT05577507View on ClinicalTrials.gov

Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

May 30, 2023

Study Completion Date

June 30, 2023

Conditions
Chronic Kidney DiseasesHemodialysis ComplicationHyperphosphatemia
Interventions
DRUG

Cholestyramine Resin 4000 MG [Questran]

cholestyramine 4 gram sachets (questran) will be administered orally three times daily for 8 weeks period trial

DRUG

Calcium Carbonate 500 MG Oral Tablet

control group will administer standard therapy calcimate 500 mg three times daily within meals

Trial Locations (1)

11511

Ain Shams university, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER